Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of the Application of Low Level Laser Light to Treat Venous Stasis Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least one venous stasis ulcer, diagnosed according to a differential diagnosis methodology that satisfies both criteria supportive of the ulcer's venous origin and criteria that eliminates the ulcer as being indicative of non-venous origin. Diagnostic criteria to evaluate satisfaction of criteria that is supportive of venous origin of the ulcer will involve an evaluation of medical history and wound history variables; physical examination of the affected leg and ulcer site; and objective testing~* Resting Ankle Brachial Pressure Index (ABPI) of 0.8 or greater~* Venous Doppler ultrasound shows reflux in the suspect vein~* Clinical Etiologic Anatomic Pathophysiologic (CEAP) Classification System Class 6~* Ulcer measures 5 to 20cm², inclusive, according to standardized computerized planimetry evaluation~* presenting venous leg ulcer has been present for 6 continuous weeks or longer~* Subject agrees to not partake in any other form of treatment for the ulcer throughout study participation, other than the standard of care treatment provided by the investigator as part of the study protocol~Exclusion Criteria:~* Satisfaction of any exclusive diagnostic criteria that is considered indicative of an ulcer being of non-venous origin (e.g. arterial or mixed origin), or as having a non-venous component. This evaluation will include consideration of medical history and wound history variables; examination of the affected leg and ulcer site; and objective tests and measurements~* Resting Ankle Brachial Pressure Index (ABPI) of less than 0.8~* Doppler ultrasound that shows absence of reflux in the suspect vein~* Fasting blood glucose (blood sugar) level of greater than 140 mg/dl that is indicative of current or potential diabetes~* Subject presents with factors that may significantly impede or delay the healing of chronic non-healing wounds, including known diabetes or other disordered glucose metabolic disease; malnutrition; collagen diseases such as Ehlers-Danlos syndrome; history of systematic glucocorticosteroid therapy; history of exogenous glucocorticosteroid therapy; and chemotherapeutic (antineoplastic) drug use~* Ulcer has significant bacterial infection, confirmed by a positive swab culture utilizing Levine's technique~* Ulcer has been present for less than 6 continuous weeks~* Ulcer is of CEAP Class 0 through 5, inclusive~* Ulcer measures less than 5cm² or greater than 20cm², according to standardized computerized planimetry evaluation~* Exposed bone tendon or fascia~* General skin disorder such as psoriasis or penicilitis~* Immunosuppressive disorder~* Hypercoagulable state~* Prior deep vein thrombosis~* Cellulites during the one-year period prior to study participation in~* Vasculitis or collagen vascular disease~* History of prior venous surgery~* Any concomitant illness(es) or medical condition(s) that would render the subject inappropriate for the study (i.e., renal failure, liver disease, connective tissue disorders, etc.)~* Active or recurrent cancer or currently receiving chemotherapy or radiation therapy~* Subject is taking a regimen of any medication(s) that may affect wound healing, including corticosteroid, chemotherapeutic and non-steroidal anti-inflammatory (NSAID) medications~* Developmental disability/significant psychological disorder that could impair the subject's ability to provide informed consent, participate in the study protocol or record study measures, including schizophrenia, bipolar disorder and psychiatric hospitalization within the last 2 years~* Females currently pregnant or lactating or intending to attempt to become pregnant during the course of intended study participation~* Involvement in litigation/receiving disability benefits related to venous stasis ulcer(s).~* Other research participation in the 30 days prior to study qualification evaluation.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Erchonia ML Scanner (MLS) (Type: ACTIVE_COMPARATOR): Erchonia MLS comprises three 17.5 milliWatts (mW) 635 nanometer (nm) light emitting diodes. The center diode is fixed at 6 inches above the venous stasis ulcer center, and the other 2 diodes rotate about this center fixed diode for 20 minutes. Total dosage delivered to the skin is 2.95 J/cm squared.
- Placebo Laser (Type: PLACEBO_COMPARATOR): Placebo Laser has the same appearance and application as the Erchonia MLS but does not emit an therapeutic output.

Based on this trial design, predict the completion outcome and termination type (if applicable).